Lexaria up after drug delivery tech shows possible benefits for COVID-19

Lexaria Bioscience

21/07/2021 15:33

** U.S.-listed shares of Canadian drug delivery platforms
maker  LEXX.O  rise as much as 52% to a near one-year high of
$10.02 
    ** Says a study in rats showed that its technology enhanced
the delivery of Colchicine - a drug being studied to reduce
overactive immune responses, called cytokine storm, associated
with COVID-19  urn:newsml:reuters.com:*:nACS7WMMva
    ** Colchicine, mainly used to treat gout, is also
occasionally used to treat a kind of heart inflammation in
children after administration of mRNA COVID-19 vaccines 
    ** Co says the study in rats also tested absorption of two
other antiviral drugs but the findings were not notable; adds it
would likely focus on colchicine
    ** Stock up nearly 34% this year, including session's gains

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))